Browse our 1,000+ Publications​

Latest Publications

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Nadeem O, et al.
Nature Medicine
April 2026
Authors and Affiliates
Omar Nadeem 1,2,3,10, David M. Cordas dos Santos 1,2,10, Sarah Nikiforow2, Anna Bosch-Vilaseca2, Elizabeth O’Donnell1,2, Robert Redd4, Kevin C. DeBraganca5, Adam S. Sperling 2,6, Yuxin Liu1,2, Caleb McEntire6, Frances Arters1,2, Colin O’Donnell3, Brendan Kineavy3, Marjorie Marto1,2, Amy Bergeron1,2, Emilie Swenson3, Kristin McHugh3, Abigail Caron3, Quentin Berry3, Hope Wei 3, Emily Durlacher 3, Elizabeth Grimm3, Francesco Corrado1,2, Nayda Bidikian1,2, Rocio Montes de Oca7, Tamar Lengil8, Denise De Wiest8, Casey Gervais2, Kevin Panaro 2, Eric L. Smith 2, Kenneth Anderson 2, Caron Jacobson2, Nikhil C. Munshi 2, Paul Richardson2, Deepu Madduri8, Jordan M. Schecter8, Craig Tendler8, Mark A. Wildgust8, Lorenzo Trippa4, Maria Victoria Mateos 9, Jerome Ritz 2 & Irene M. Ghobrial 1,2 1Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA. 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA. 4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. 5Janssen Research & Development, Raritan, NJ, USA. 6Brigham and Women’s Hospital, Boston, MA, USA. 7Johnson & Johnson, Spring House, PA, USA. 8Johnson & Johnson, Raritan, NJ, USA. 9Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain. 10These authors contributed equally: Omar Nadeem, David M. Cordas dos Santos.

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Gay F, et al.
Nature Medicine
April 2026
Authors and Affiliates
Francesca Gay  1 , Wilfried Roeloffzen  2 , Meletios A. Dimopoulos  3,4, Laura Rosiñol  5 , Marjolein van der Klift6 , Roberto Mina  1 , Albert Oriol  7 , Eirini Katodritou8 , Ka Lung Wu9 , Paula Rodríguez Otero10, Roman Hájek11,12, Elisabetta Antonioli13, Mark van Duin14, Mattia D’Agostino1 , Joaquín Martínez-López  15, Elena M. van Leeuwen-Segarceanu16, Elena Zamagni17,18, Niels W. C. J. van de Donk  19, Katja C. Weisel  20, Luděk Pour21, Jakub Radocha22, Angelo Belotti23, Fredrik Schjesvold  24,25, Joan Bladé  4 , Hermann Einsele  26, Pieter Sonneveld  14,27, Mario Boccadoro28 & Annemiek Broijl14 1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy. 2 Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands. 3 Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 4 Department of Medicine, Korea University, Seoul, South Korea. 5 Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS, and PETHEMA/GEM, Barcelona, Spain. 6 Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands. 7 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain. 8 Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece. 9 ZAS Cadix, Antwerp, Belgium. 10Cancer Center Clínica Universidad de Navarra, Pamplona, Spain. 11Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic. 12Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. 13Hematology Unit, AOU Careggi, Florence, Italy. 14Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 15Hematology Department, Hospital Universitario de Octubre, Medicine Department Complutense University, imas12, CNIO, Madrid, Spain. 16Department of Hematology, St. Antonius Hospital, Nieuwegein, the Netherlands. 17IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia ‘Seràgnoli’, Bologna, Italy. 18Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy. 19Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands. 20Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany. 21Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. 224th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic. 23Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy. 24Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway. 25KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway. 26Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany. 27European Myeloma Network (EMN), Rotterdam, the Netherlands. 28European Myeloma Network (EMN), Turin, Italy

Final clinical data of a phase 1 dose-escalation study ofWVT078, a BCMA£CD3 bispecific antibody, alone and incombination with γ-secretase inhibitor WHG626 in patientswith relapsed and/or refractory multiple myeloma

Schjesvold F, et al.
Cancer
April 2026
Authors and Affiliates
Fredrik Schjesvold MD, PhD1,2 | Andrew Spencer MBBS, FRACP, FRCPA, DM3 |Yael C. Cohen MD4,5 | Enrique M. Ocio MD, PhD6 | Jordi Lopez-Pardo MD7 |Anna Maria Cafro MD8 | Natalie S. Callander MD9 | Jonathan L. Kaufman MD10 |Meera Mohan MD, MS11 | Martin Wermke MD12 | Noriko Doki PhD, MD13 |Rebecca Kan MPH14 | Pedro Milanez-Almeida PhD14 | Andrew Stein PhD14 |Gina Trabucco MSc14 | Stan Ye PhD14 | Karolina Kulec MSc15 |Romain Sechaud PhD16 | Souvik Banerjee PhD17 | Huiqin Zhong PhD18 |Clinton Lai MBChB, FFPM18 | Philipp J. Rauch MD16 | Marc S. Raab MD191Oslo Myeloma Center, Department of Hematology, OSLO University Hospital, Oslo, Norway2KG Jebsen Center for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway3The Alfred Hospital, Monash University, Melbourne, Victoria, Australia4Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel5Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel6Hospital Universitario Marqués de Valdecilla, Idival, Santander, Spain7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain8Department of Hematology, GOM Niguarda Hospital, Milan, Italy9Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA10Winship Cancer Institute, Emory University, Atlanta, Georgia, USA11Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA12NCT/UCC Early Clinical Trial Unit, Universitatsklinikum Carl Gustav Carus an der Technische Universitat, Dresden, Germany13Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan14Novartis Biomedical Research, Cambridge, Massachusetts, USA15Novartis Ireland Limited, Dublin, Ireland16Novartis Biomedical Research, Basel, Switzerland17Novartis Healthcare Pvt, Ltd, Hyderabad, India18Novartis Institutes for BioMedical Research, Shanghai, China19Heidelberg Myeloma Center Department of Medicine V, Medical Faculty and University Hospital, Heidelberg, Germany

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Dytfeld D, et al.
Lancet Haematology
April 2026
Authors and Affiliates
Dominik Dytfeld 1, Tomasz Wróbel 2, Krzysztof Jamroziak 3, Tadeusz Kubicki 1, Paweł Robak 4, Anna Puła 5, Adam Walter-Croneck 6, Jarosław Czyż 7, Agata Tyczyńska 8, Agnieszka Druzd-Sitek 9, Krzysztof Giannopoulos 10, Adam Nowicki 11, Tomasz Szczepaniak 12, Anna Łojko-Dankowska 1, Magdalena Matuszak 1, Lidia Gil 1, Bartosz Puła 13, Justyna Rybka 2, Maciej Majcherek 2, Lidia Usnarska-Zubkiewicz 2, Łukasz Szukalski 7, Agnieszka Końska 14, Jan Maciej Zaucha 8, Jan Walewski 9, Damian Mikulski 4, Olga Czabak 10, Tadeusz Robak 15, Oscar B Lahoud 16, Jeffrey A Zonder 17, Jennifer H Cooperrider 18, Benjamin A Derman 18, Theodore Karrison 18, Andrzej J Jakubowiak 19 1Poznan University of Medical Sciences, Poznan, Poland. 2Wroclaw Medical University, Wroclaw, Poland. 3Medical University of Warsaw, Warsaw, Poland. 4Medical University of Lodz, Lodz, Poland. 5Medical University of Lodz, Lodz, Poland; University of Chicago, Chicago, IL, USA. 6Medical University of Lublin, Lublin, Poland; Department of Haematology and Bone Marrow Transplantation Centre of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland. 7Department of Haematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland. 8Department of Haematology and Transplantology, Medical University of Gdansk, University Clinical Center Gdansk, Gdansk, Poland. 9Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw, Poland. 10Medical University of Lublin, Lublin, Poland. 11Greater Poland Cancer Centre, Poznan, Poland. 12Poznan University of Medical Sciences, Poznan, Poland; St James's Hospital, Dublin, Ireland. 13Institute of Haematology and Blood Transfusion, Warsaw, Poland; Department of Haematology, Medical University of Lodz, Lodz, Poland. 14Institute of Haematology and Blood Transfusion, Warsaw, Poland. 15Department of Haematology, Medical University of Lodz, Lodz, Poland. 16NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA; New York University Grossman School of Medicine, New York, NY, USA. 17Wayne State University Karmanos Cancer Institute, Detroit, MI, USA. 18University of Chicago, Chicago, IL, USA. 19University of Chicago, Chicago, IL, USA. Electronic address: ajakubowiak@medicine.bsd.uchicago.edu.

Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study

Orlowski R, et al.
Blood
February 2026
Authors and Affiliates
Robert Orlowski (The University of Texas MD Anderson Cancer Center, United States) Meletios Dimopoulos (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece, Department of Medicine, Korea University, Seoul, Republic of Korea, Greece) Xavier Leleu (Hopital La Miletrie, France) Thierry Facon (Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, France) Tadao Ishida (Japanese Red Cross Medical Center, Japan) Roman Hajek (University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic) Ivan Spicka (Charles University and General Faculty Hospital, Prague, Czech Republic) Joanna Romejko-Jarosinska (Marie Sklodowska-Curie National Research Institute of Oncology, Poland) Vladimir Vorobyev (S.P. Botkin Hospital, Russian Federation) Britta Besemer (University Hospital of Tuebingen, Germany) Sevgi Kalayoglu Besisik (Istanbul University Istanbul Medical Faculty, Turkey) Pawel Robak (Medical University of Łódź, Łódź, Poland, Poland) Tomas Jelínek (University Hospital Ostrava, Czech Republic) Hartmut Goldschmidt (Universitätsklinikum Heidelberg, Med. Klinik V, GMMG-Studygroup, Germany) Thomas Martin (University of California, San Francisco, United States) Mohamad Mohty (Hôpital Saint-Antoine, INSERM UMRs 938, and Université Sorbonne, France) Sandrine Macé (Sanofi, France) Ercem Kodas (Sanofi, France) Christina Tekle (Sanofi, United States) Andrea Shafer (Sanofi, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France)

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

Ruan J, et al.
Blood Advances
February 2026
Authors and Affiliates
Jia Ruan (Weill Cornell Medicine, United States) David Bond (The Ohio State University, United States) Bijal Shah (Moffitt Cancer Center, United States) John Allan (Weill Medical College of Cornell University, New York Presbyterian Hospital, United States) Sarah Rutherford (Weill Cornell Medicine, United States) Caitlin Gribbin (Weill Cornell Medical College, United States) Zhengming Chen (Weill Cornell Medicine, United States) Bhavneet Bhinder (Weill Cornell Medical College, United States) Wayne Tam (Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States) Davide Rossi (Oncology Institute of Southern Switzerland, Switzerland) Jenny Xiang (Weill Cornell Medical College, United States) Brittany Hobbie (Weill Cornell Medicine, United States) Melinda Harbhajan (Weill Cornell Medicine, United States) Tejasvi Sahni (Weill Cornell Medicine, United States) Gui Zhen Chen (University of Washington/Fred Hutchinson Cancer Research Center, United States) Michael Sigouros (Caryl and Israel Englander Institute for Precision Medicine, United States) Giorgio Inghirami (Weill Cornell Medicine, United States) Selina Chen-Kiang (Cornell University Medical College, United States) Olivier Elemento (Weill Cornell Medical College, United States) Kami Maddocks (The Ohio State University, United States) John Leonard (Weill Medical College of Cornell University and New York Presbyterian Hospital, United States) Peter Martin (Weill Cornell Medical College, United States)

Minimal Disease Detection by Immunoglobulin High-Throughput Sequencing in Pediatric Burkitt Lymphoma

Craig S, et al.
Blood Advances
February 2026
Authors and Affiliates
Stephanie M. Craig1* , K. Riley Okeson2* ; Diana G. Adlowitz1,3; Cameron Baker4 ; Philip J. Rock3 ; Richard Burack3 ; Carol Fries1,3 1: Department of Pediatrics, University of Rochester, Rochester, NY, USA 2: University of Rochester School of Medicine and Dentistry, Rochester, NY, USA 3: Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, USA 4: Genomics Research Center, University of Rochester, Rochester, NY, USA 5: Department of Biomedical Genetics, University of Rochester, Rochester, NY, USA

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy

Bal S, et al.
Blood
January 2026
Authors and Affiliates
Susan Bal MD1 , Gayathri Ravi MD1 , Binod Dhakal MD2 , Natalie S Callander MD3 , Eva Medvedova MD4 , Bhagirathbhai R. Dholaria MD5 , Smith Giri MD, MS1 , Kelly N. Godby MD1 , Rebecca W Silbermann MD2 , Fady M. Mikhail MD, PhD6 , Forest Huls MD7 , Vishnu Reddy MD7 , Luciano J. Costa MD, PhD1 . 1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 2 Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 3Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI 4Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 5Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 6Department of Genetics, University of Alabama at Birmingham School of Medicine, Birmingham, AL 7Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL

Three‑year follow‑up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL‑3

Izutsu K, et al.
International Journal of Hematology
January 2026
Authors and Affiliates
Koji Izutsu1  · Daigo Akahane2  · Tomomi Toubai3  · Toko Saito4  · Yuko Mishima5  · Tomoaki Fujisaki6  · Momoko Nishikori7  · Takahiro Kumode8  · Youko Suehiro9  · Kenji Ishitsuka10 · Poliana Patah11 · Ami Takahashi12 · Barbara D’Angelo Månsson13 · Elena Favaro13 · Noriko Fukuhara14 1 Department of Hematology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan 2 Department of Hematology, Tokyo Medical University, Tokyo, Japan 3 Department of Internal Medicine III, Division of Hematology and Cell Therapy, Faculty of Medicine, Yamagata University, Yamagata, Japan 4 Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan 5 Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 6 Department of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan 7 Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 8 Department of Hematology and Rheumatology, Kindai University, Osaka, Japan 9 Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan 10 Department of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan 11 AbbVie, North Chicago, IL, USA 12 Genmab, Tokyo, Japan 13 Genmab, Copenhagen, Denmark 14 Department of Hematology, Tohoku University, Sendai, Japan

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Einsele H, et al.
Lancet Oncology
January 2026
Authors and Affiliates
Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C Cohen,Simon J Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh,Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M Schecter, Nikoletta Lendvai,Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, Rakesh PopatUniversitätsklinikumWürzburg, Medizinische Klinikund Poliklinik II, Würzburg,Germany (Prof H Einsele MD);Cancer Center ClinicaUniversidad de Navarra, CIMA,IDISNA, Pamplona, Spain(Prof J San-Miguel MD PhD);Medical College of Wisconsin,Milwaukee, WI, USA(Prof B Dhakal MD); Serviced’Hématologie, CHU HotelDieu, Nantes, France(Prof C Touzeau MD); CRCINA,INSERM, CNRS, Universitéd’Angers, Université de Nantes,Nantes, France (Prof C Touzeau);Site de Recherche Intégrée surle Cancer (SIRIC), ILIAD, INCA-DGOS-Inserm_12558, Nantes,France (Prof C Touzeau); Serviced’Hématologie et ThérapieCellulaire, Hôpital La Milétrie(Prof X Leleu MD PhD), andCentre d’Investigation CliniqueINSERM 1402 (Prof X Leleu),Poitiers University Hospital,Poitiers, France; AmsterdamUniversity Medical Center, VrijeUniversiteit Amsterdam,Amsterdam, Netherlands(Prof N W C J van de Donk MD PhD);Stanford University School ofMedicine, Stanford, CA, USA(Prof S Sidana MD); InstitutCatalà d’Oncologia(A Oriol MD PhD), and InstitutJosep Carreras (A Oriol),Hospital Germans Trias i Pujol,Badalona, Spain; Tel-AvivSourasky (Ichilov) MedicalCenter, Gray Faculty of Medicaland Health Sciences, Tel AvivUniversity, Tel Aviv, Israel(Prof Y C Cohen MD); PeterMacCallum Cancer Centre,Melbourne and RoyalMelbourne Hospital, Melbourne, VIC, Australia(Prof S J Harrison MBBS PhD);Translation Laboratory, Centreof Excellence in CellularImmunotherapy, PeterMacCallum Cancer Centre,Melbourne, VIC, Australia(Prof S J Harrison); Sir PeterMacCallum Department ofOncology, University ofMelbourne, Parkville, VIC,Australia (Prof S J Harrison);University Hospital ofSalamanca–IBSAL–CIC–CIBERONC, Salamanca, Spain(Prof M-V Mateos MD PhD);Hospital 12 de Octubre,Complutense University CNIO,MIC, Madrid, Spain(Prof J Martínez-López MD PhD);Fondazione IRCCS IstitutoNazionale dei Tumori Milano,University of Milano, Milan,Italy (Prof P Corradini MD);Centre Hospitalier Lyon Sud,Pierre-Bénite, France(L Karlin MD); Johnson &Johnson, Shanghai, China(D Chen MS); Johnson &Johnson, Apex, NC, USA(Q Li MS); Johnson & Johnson,Raritan, NJ, USA (T-m Yeh MS,A Ghosh MD PhD,J M Schecter MD,N Lendvai MD PhD); Johnson &Johnson, Spring House, PA,USA (K Li MS, V Plaks LLB PhD);Johnson & Johnson, Zug,Switzerland (A Slaughter PhD);Johnson & Johnson, BuenosAires, Argentina(C Lonardi PharmD); Johnson &Johnson, Beerse, Belgium(N Benachour MS); Johnson &Johnson, Neuss, Germany(M Vogel MD PhD); LegendBiotech USA, Somerset, NJ,USA (M Koneru MD PhD,N Patel BM BCh,E Florendo MSN); Royal PrinceAlfred Hospital, Sydney, NSW,Australia(Prof P J Ho MBBS DPhil);University of Sydney, Sydney,NSW, Australia (Prof P J Ho);University College LondonHospitals, NHS FoundationTrust, London, UK(R Popat MD PhD)
Previous Next